Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
4.330
-0.390 (-8.26%)
At close: Feb 21, 2025, 4:00 PM
4.410
+0.080 (1.85%)
After-hours: Feb 21, 2025, 5:45 PM EST
Company Description
Mangoceuticals, Inc. develops, markets, and sells various men’s wellness products and services through a telemedicine platform in the United States.
It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name.
The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.
The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Mangoceuticals, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Mar 21, 2023 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Jacob Cohen |
Contact Details
Address: 15110 North Dallas Parkway, Suite 600 Dallas, Texas 75248 United States | |
| Phone | 214 242 9619 |
| Website | mangoceuticals.com |
Stock Details
| Ticker Symbol | MGRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001938046 |
| CUSIP Number | 56270V106 |
| ISIN Number | US56270V1061 |
| Employer ID | 87-3841292 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Jacob D. Cohen | Co-Founder, Chief Executive Officer and Chairman |
| Eugene M. Johnston | Chief Financial Officer |
| Amanda Elizabeth Hammer | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 19, 2025 | 8-K | Current Report |
| Feb 18, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 424B3 | Prospectus |
| Feb 10, 2025 | 424B3 | Prospectus |
| Feb 7, 2025 | 8-K | Current Report |
| Feb 6, 2025 | PRE 14A | Other preliminary proxy statements |
| Jan 31, 2025 | 8-K | Current Report |
| Jan 22, 2025 | SCHEDULE 13G | Filing |